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Summary N-(4-hydroxyphenyl) retinamide (4-HPR) is a synthetic retinoid which reduces the incidence of
experimental tumours in animals and has been chosen for its weak toxicity to be tested as a chemopreventive
agent in humans. The mechanism of antineoplastic action is still unknown but a possible immunoenhancing
effect may be postulated. We investigated the NK activity of PBMC from a group of women treated with
4-HPR as a part of a large scale randomised phase III trial on chemoprevention of controlateral disease in
mastectomised women. After 180 days of treatment the NK activity was augmented 1.73 times as compared to
that of patients given a placebo. The NK activity of PBMC from 4-HPR treated women is maximised, being
higher than the basal and even the rIL-2 or alfa-rIFN stimulated activity of controls. For this reason in the
majority of cases it cannot be further augmented by incubation with either rIL-2 or alfa-rIFN in vitro. The
increased NK activity of 4-HPR treated women is not due to an enhanced production of endogenous IL-2,
because PBMC cultures from patients treated with 4-HPR or placebo, incubated in vitro with a panel of
different stimulators (recall antigens, PHA, allogeneic and xenogeneic cells) produce similar amounts of IL-2.
The functional activity, but not the number of NK cells is increased in 4-HPR treated women. The mechanism
by which 4-HPR stimulates NK activity is not a function of direct action on NK cells. Indeed incubation of
PBMC from blood donors with 4-HPR or its major metabolite N-(4-methoxyphenyl) retinamide (4-MPR)
does not modify their natural cytotoxicity.
Vitamin A (Retinol) and some of its naturally occurring or
synthetic analogues or derivatives (Retinoids) exhibit anti-
neoplastic activity against epithelial tumours induced by
chemical carcinogens in vivo or in vitro. Inhibition of the
growth and development of transplantable tumours both in
vivo and in vitro has also been demonstrated. Unfortunately,
clinical use of these compounds in the prevention and treat-
ment of human cancers has been slowed because of their
toxicity. For this reason, over 2000 synthetic analogues of
retinoids have been produced and N-(4-hydroxyphenyl)
retinamide (4-HPR) appeared to be one of a few that has
retained the beneficial therapeutic effect with reduced tox-
icity. In particular, 4-HPR inhibits the development of breast
cancer induced in rats by N-methyl-N-nitrosourea, and it is
not stored in the liver, so that hepatotoxicity that results
from the feeding of other chemopreventive retinoids is not
likely to occur (Hultin et al., 1986).
The aforementioned characteristics of 4-HPR led to its use
for the prevention of controlateral disease in breast cancer
patients with no axillary lymph node metastases who
previously underwent radical surgery. In March 1987, a large
scale randomised phase III trial was started at the Istituto
Nazionale Tumori of Milano. The protocol planned a 5-year
4-HPR administration at 200 mg/day p.o., including a 3-day
drug interruption at the end of each month, vs a control
group receiving a placebo. Details of this trial are reported
elsewhere (Rotmensz et al., 1991). The mechanism by which
4-HPR prevents mammary cancer, at least in rodents, is still
unknown, although it has been reported that vitamin A and
Retinoids may modulate both cellular immunity and cytotox-
icity mediated by natural killer (NK) cells. Several papers
indicate an important in vivo role for NK cells in tumour
resistance but, as far as we know, their activity in 4-HPR
treated women has not yet been studied.
The experiments described in this study demonstrate that
the natural cytotoxicity of peripheral blood mononuclear
cells (PBMC) is significantly (P<0.005) higher in 4-HPR
treated women than in controls, i.e. mastectomised women
receiving a placebo, and that it is maximised. Indeed, incuba-
tion of their PBMC with rIL-2 and alfa-rIFN, which usually
augments the NK activity in vitro, did not further increase
natural cytotoxicity, as opposed to that of controls. It has
also been demonstrated that the functional acitivity, but not
the number of NK cells is increased in 4-HPR treated women
and that such an increase is independent from IL-2 blood
levels. Although it seems likely that 4-HPR acts through
some of its metabolites, the experiments so far carried out
with the major and only one available at present for
experimental purposes (N-(4-methoxyphenyl) retinamide = 4-
MPR) did not validate the hypothesis. However further
experiments will be performed after isolation of substantial
amounts of other minor metabolites.
Materials and methods
Participants
The patients are 31 breast cancer women, aged 35-65 years,
with no axillary lymph node metastases, who previously
underwent radical surgery, and are participating in the above
mentioned phase III trial. In short, 17 and 14 of them
received, respectively, 200 mg 4-HPR p.o. daily or a placebo.
Twenty-four females, aged 35-55 years, taken from blood
donors of the Istituto Nazionale Tumori of Milano were also
evaluated.
Blood samplesfor PBMC separation and analytical procedures
Blood samples were collected in heparinised tubes at zero
time, that is, before the starting of 4-HPR or placebo
administration and 6 months later, 12 h after the last dose.
Some tubes were used for PBMC separation as described
elsewhere (Villa et al., 1991). Some other tubes, wrapped in
aluminium foil to prevent exposure to light, were centrifuged
at 1500 g for 15 min at 4°C and plasma, separated in the
dark, was kept frozen at - 20°C until analytical procedures
for no more than 3 weeks.
Target cells
K562 cells (human myelogenous leukaemia with haemato-
genic potential) were grown in suspension in RPMI 1640 plus
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10% foetal bovine serum (FCS) and were labelled by
exposure for 1 h to 200liCi Na (5"Cr) 04.
Cytotoxicity assay
NK activity was assessed in a 18 h 5'Cr release assay by
adding 3 x 103 target cells in 0.1 ml RPMI to 0.08 ml of
effector cells at varying concentrations, to obtain the desired
final effector to target cell ratios (E:T), 50:1, 25:1, 12:1, 6: 1.
NK assays were carried out in triplicate, in round-bottomed
microtitre plates (Costar Corporation, Cambridge, MA) in a
total volume of 0.2 ml. The microtitre plates were centrifuged
for 3 min at 80g and then incubated for 18 h at 37°C in a
humidifed 5% CO2 incubator. To harvest the assay, the
plates were centrifuged at 450g for 5 min and 0.1 ml of
supernatant was removed for counting. Spontaneous release
was evaluated by omitting effector cells, and maximum
release was determined by incubating targets in 2 N HCI,
which releases 75-95% of total counts. Percent cytotoxicity
was calculated as:
c.p.m. experimental - c.p.m. spontaneous x 100
c.p.m. maximum - c.p.m. spontaneous
rIL-2 and alfa-rIFN activated cytotoxicity
A total of 1.5 x 106 PBMC in I ml of RPMI were incubated
for 1 h at 37'C with 1.000 U of alfa-rIFN (Roche, Basel,
CH), or overnight at 37'C with 600 U of rIL-2 (Biogen,
Cambridge, MA). Treated PBMC were then tested for
cytotoxicity in a 18 h 5'Cr release assay as described above.
NK cell immunophenotyping
Indirect fluorescence of PBMC with a monoclonal antibody
(MoAb) Leu 1 b (anti CD16) (Beckton Dickinson, Sun-
nyvale, CA) was measured with a FACSscan fluoro-
cytometer.
IL-2 production
For IL-2 production, 0.1 ml of PBMC was added per well to
96-well flat-bottom tissue culture plates (Costar Corporation,
Cambridge, MA). The PBMC were cultured without stim-
ulation or were stimulated with (a) FLU: influenza virus
vaccine, prepared with a mixture of A/Taiwan, A/Shangai,
B/Victoria, 24fig ml-' (final dilution 1:1000); (b) ALLO: a
pool of irradiated (50 Gy) PBMC from two unrelated blood
donors (2 x 106 well); (c) PHA (Gibco, Grand Island, NY)
diluted 1:200 and (d) XENO: splenic cells from mouse
C57B6 (2 x 106 well). Pooled human plasma was added to
each well (1:20 final concentration) 1 h after sensitisation of
the PBMC. Supernatants of stimulated and unstimulated
cultures were harvested 7 days later and frozen at - 20°C.
For studies of IL-2 production, a MoAb anti-IL-2 receptor
(Beckton Dickinson, Rutherford, NJ) was added at the initia-
tion of culture at a final concentration of 10 ,ug ml ', in
order to block IL-2 consumption (Uchiyama et al., 1981).
The supernatant IL-2 activity was assessed as the ability to
stimulate the proliferation of the IL-2 dependent cell line,
CTLL. This cell line is stimulated by human IL-2, but not by
human IL-4. Assay cultures consisted of 8 x 103 CTLL/well
at five successive 2-fold dilutions of supernatant. Twenty-four
hours later, the cultures were pulsed with 1 ytCi of [3H]-
thymidine (ICN Radiochemicals, Irving, CA) and harvested
18 h later. Results are expressed as mean c.p.m. for three
replicate wells for a given supernatant dilution. Standard
errors were always < 10% of the mean values. The concen-
tration of anti-IL-2 receptor antibody used in the initial
culture did not inhibit CTLL proliferation.
PBMC incubation with 4-HPR and 4-MPR
The NK activity of PBMC from 12 blood donors was
assessed after 18 h incubation of PBMC with different
amounts (10-8, I0-, 106 and 10-5 M final concentration) of
4-HPR and 4-MPR.
Analyticalprocedures
Plasma collected in the dark and kept frozen at - 20°C was
gently thawed and analysed for 4-HPR, 4-MPR and Retinol
as elsewhere described (Formelli et al., 1989).
Calculations and statistical analysis ofdata
Student's t-tests were performed for the comparison of two
independent samples of unequal size as described by
Snedecor & Cochran (1980), and P values were determined.
Normal thresholds for basal or stimulated NK activity have
been calculated as mean values of control - 2 s.d.; all sub-
jects showing NK activity greater than two standard devia-
tions above the mean of controls were considered 'normally
responsive'.
Results
Basal NK activity and NK immunophenotype
Basal NK activity at zero time, expressed as percent lysis, is
shown in Figure 1 and was as follows: (1) 57.76 ± 14.63 s.d.
(17 women to be treated with 4-HPR), (2) 52.08 ± 10.60 (14
women to receive a placebo), (3) blood donors: 64.76 ±
12.01.
At this time, only one patient of the first group and two of
the second were under the normal threshold of activity,
calculated as mean value of blood donors - 2 s.d. (= 40.74).
After 180 days of treatment, the NK activity was as fol-
lows: (1) 4-HPR = 70.35 ± 20.49 and (2) placebo = 48.36 ±
15.96.
These results show that NK activity is increased in 4-HPR
women even above the normal level, and is almost unvaried
in placebo treated women, respectively, as compared to that
of blood donors. The difference between 4-HPR and placebo
treated women is statistically significant (P<0.005).
We point out that all 4-HPR treated women show a
definite increase of NK activity except three patients who
exhibit a decrease of their activity quite under the normal
threshold. We were not able to find any data in their clinical
history to explain this difference.
The three patients whose NK level dropped on 4-HPR
have not relapsed at the time of printing of this report, that
is, about 2 years after the beginning of chemoprevention with
the above synthetic retinoid. The percentage of NK cells
stained with MoAb Leu 1 Ib (anti CD16) was of 21.30 ±
11.34 s.d. vs 21.07 + 7.79; and 22.66 ± 13.76 vs 22.16 ± 7.00,
in 4-HPR and placebo group, respectively, prior and after
180 days of treatment, thus showing that the functional
activity, but not the number of NK cells is increased in
4-HPR treated women.
We point out that the absolute number of lymphocytes in
both experimental group was always within the normal
range, as assessed by routine differential WBC counts.
4-HPR, 4-MPR and Retinol in the blood
Figure 2 shows that after 180 days of 4-HPR treatment the
blood concentration of 4-HPR, 4-MPR and Retinol are as
follows: 274.21 ngml-', 201.07 ngml-' and 177 ngml-'. The
normal blood levels of Retinol are 506 ± 102 ng ml-'. These
results confirm that the administration of 4-HPR and their
metabolites induces a sharp decrease of Retinol concentra-
tion.
Cytokine stimulated NK activity after 4-HPR treatment
In order to evaluate the responsiveness of NK cells to rIL-2
and alfa-rIFN, PBMC were incubated with these two
activators for 18 and 1 h respectively, and the NK activityRETINOIDS AND NK CELLS 847
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Figure 1 Basal NK activity expressed as percentage lysis of
K562 cells, after 18 h incubation with PBMC from 4-HPR or
placebo patients and from healthy donors. For each patient the
NK activity prior (0) and after (0) 180 days of treatment is
indicated. Vertical line (.........) represents the normal basal
threshold, calculated as mean value of healthy donors - 2 s.d.
The E:T ratio of 50:1 was utilised for calculation.
0
against K562 cells was measured. The results of these
experiments are summarised in Figure 3. IL-2 had a marked
enhancing activity on PBMC from all three groups. The
basal vs IL-2 activated cytotoxicity expressed as percentage
lysis ± s.d. was equal to 48.36 ± 15.96 vs 86.72 ± 10.69 for
placebo patients (79% increase) and to 62.13 ± 11.08 vs
88.2 ± 10.14 for blood donors (46% increase). For 4-HPR
treated women the basal vs IL-2 activated cytotoxicity after
180 days treatment was equal to 70.35 ± 20.49 vs 89.92 ±
9.16 (27% increase). The normal threshold for IL-2
stimulated NK activity, calculated as mean percentage
cytotoxicity of blood donors - 2 s.d., was = 67.92.
The per cent increase was less marked in 4-HPR treated
women because their basal activity at this time was higher
and, in some cases, already near to the maximum. Indeed,
even before IL-2 stimulation, only 6/17 cases showed an
activity under, and as many as 11/17 above the normal IL-2
stimulated threshold.
Incubation with IL-2 increased the NK activity of the
former six cases above stimulated threshold, leaving almost
unvaried the activity of the later 11 cases. PBMC from all
but one placebo treated women, after IL-2 incubation,
showed an activity above the normal IL-2 stimulated
threshold.
The responsiveness to alfa-rIFN was less marked; the basal
vs IFN activated cytotoxicity expressed as percentage
lysis ± s.d. was equal to 48.36 ± 15.96 vs 63.63 ± 18.03 (32%
increase) for placebo patients, to 60.13 ± 11.08 vs 83.6 ± 9.85
(39% increase) for blood donors and to 70.35 ± 20.49 vs
80.05 ± 13.15 for 4-HPR treated women (14% increase).
As far as concerns individual patterns, the basal NK
activity in 4-HPR treated women was already up to the
alfa-rIFN stimulated threshold of blood donors in 12/17
cases; following incubation 16/17 cases went above the alfa-
rIFN stimulated threshold. On the other hand, only 5/11
placebo treated patients, after the incubation with alfa-rIFN,
showed a NK activity above the normal activated threshold.
In summary it appears that PBMC from blood donors and
placebo treated women behave almost in the same way and
are more stimulated after incubation with rIL-2 than with
alfa-rIFN. The NK activity of PBMC from 4-HPR treated
women is already maximised in most cases and can no longer
be significantly increased by incubation with either one of the
two cytokines.
IL-2production
To test the ability of PBMC to produce IL-2 in vitro in
response to different stimulators, PBMC were cultured for 7
days with FLU, ALLO, PHA and XENO, in presence of the
MoAb anti-IL-2 receptor, to prevent IL-2 consumption. At
the end of culture period the supernatants were harvested
and tested for IL-2 content by assessing their capacity to
support the proliferation of the IL-2 dependent CTLL cell
line; normalised IL-2 responses expressed as absolute c.p.m.,
supernatant dilution of 1:4 has been utilised for calculation.
The results, as shown in Table I, show that IL-2 production
by PBMC of4-HPR treated patients is unvaried as compared
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Figure 2 Retinol (ROL), 4-HPR and MPR concentrations in plasma of patients prior and after 180 days of treatment with
4-HPR.
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Figure 3 Effect of rIL-2 a, and alfa-rIFN b, stimulation on the NK activity of PBMC from patients treated with 4-HPR or
placebo for 180 days and from healthy donors. The NK activity expressed as percentage lysis of K562 cells and the E:T ratio of
50:1 was utilised for calculation. For each patient the NK activity prior (0) and after (A) stimulation with rIL-2 is indicated. The
horizontal lines represent the normal threshold of basal (. ) and stimulated ( ) NK activity, calculated as mean value of
healthy donors - 2 s.d.
Table I IL-2 production of PBMC cultures from patients prior (Ti) and after (T2) 180 days of treatment with
4-HPR or placebo, stimulated with FLU, ALLO, PHA and XENO assessed by CTLL proliferation bioassay. The
data are expressed as absolute c.p.m., supernatant dilution 1:4was utilised forcalculation; s.e. wereapproximately
< 10% of mean values
Treatment
FLU ALLO PHA XENO NIL
Patients Ti T2 Ti T2 Ti T2 Ti T2 Ti T2
4-HPR 17818 19676 48850 40243 94302 108557 4579 8347 1222 1169
Placebo 19494 26929 32516 34445 99022 92191 5297 6569 681 846
PBMC incubation with 4-HPR and 4-MPR
In order to evaluate the effect of 4-HPR and 4-MPR on the
NK activity in vitro, PBMC from 12 blood donors were
incubated for 18 h with different amounts of 4-HPR and
4-MPR.
The basal vs 4-HPR activated cytotoxicity expressed as per
centage lysis is reported in Figure 4, which shows that neither
4-HPR nor 4-MPR modify the NK activity of PBMC.
Discussion
The results of this study demonstrate that the expression of
human natural cytotoxicity is modulated in vivo by effect of
long term administration p.o. of the putative anti-tumour
agent 4-HPR. As shown in Figure 1, the basal NK activity of
mastectomised women treated for 6 months with 4-HPR, was
augmented about 1.73 times as compared to that of blood
donors from our Institute. These findings are in agreement
with other reports showing that: (1) wild type BALB/c mice
given retinol only had a NK activity about 1.16 times higher
than that ofcontrols (Fraker et al., 1986) and, (2) vegetarians
have a blood carotene (provitamin A) concentration and a
NK activity significantly higher, by a factor of 2.0, than that
of their omnivorous controls. This enhanced natural cytotox-
icity may be one of the factors contributing to the lower
cancer risk shown by vegetarians (Malter et al., 1989). Some
controversial data are reported by Jemma et al. (1986), who
refers that feeding retinol to man and mice brings about an
augmentation of NK activity in the murine model but not in
humans. Toads fed retinoic acid have enhanced NK activity
in comparison with untreated controls (Sadek et al., 1987). In
contrast, preincubation of toad PBMC in vitro with retinoic
acid did not modify the activity of NK cells.
Treatment of human and mouse PBMC with retinol and
retinoids in vitro has been studied with some degree of con-
troversy concerning increase (McCormick et al., 1985; Jemma
et al., 1986) or invariability (Sadek et al., 1987; Sidell et al.,
1985) in NK cell activity. In summary it may be stated that,
with few exceptions, in vivo administration of retinol and
retinoids, but not in vitro preincubation with the same com-RETINOIDS AND NK CELLS 849
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Figure 4 Effect on the NK activity of 18 h incubation of PBMC from 12 blood donors with different 4-HPR a, and 4-MPR b.
amounts. Neither 4-HPR nor 4-MPR modify the NK activity of PBMC.
pounds, enhances the NK cytotoxicity. As far as we know,
no published data are available on the effects of in vitro
4-HPR incubation of human PBMC on the natural cytotox-
icity. It is possible that 4-HPR may act as a prodrug that
releases a metabolite in the tissues (Fraker et al., 1986;
McCormick et al., 1985) which might be active in vio, but
not in vitro, on the NK activity. In this connection it is worth
remembering that 4-HPR feeding to patients with cancer
brings about a rapid and significant decrease in plasma
retinol and Retinol Binding Protein (RBP) concentration,
and an outstanding increase of its major metaboilite 4-MPR
(Figure 2), while the increase in the NK activity due to oral
retinol administration is dose-dependent, at least in the
murine models (Jemma et al., 1986). and correlates with an
increased blood retinol concentration (Fraker et al., 1986). It
has also been reported that addition of 4-HPR to human
plasma at 37°C in vitro does not cause a change in the
endogenous plasma retinol or RBP levels, indicating that
there is no direct chemical interaction between 4-HPR and
retinol or RBP (Peng et al., 1989). Therefore, we performed
some experiments on 4-HPR, and 4-MPR incubation of
PBMC from blood donors in order to ascertain its influence
on the natural cytotoxicity in vitro. The NK activity is never
statistically different from that of controls in both cases.
Following incubation with rIL-2 and alfa-rIFN the NK
cell activity of PBMC from 4-HPR treated women showed
only a 27% and 14% increase over the basal cytotoxicity,
respectively. In contrast, rIL-2 and alfa-rIFN incubation of
PBMC from placebo treated women and blood donors
caused a sharp 79% and 46% increase of NK activity over
the basal cytotoxicity, respectively.
The basal NK activity of PBMC from 4-HPR treated
women was already up to the basal or rIL-2 and alfa-rIFN
stimulated threshold in the vast majority of cases and,
therefore, could no longer be significantly augmented by
incubation with either one of the cytokines in vitro. The
opposite is true for PBMC from placebo treated women and
blood donors, whose NK activity was markedly increased by
r-1L2 and alfa-rIFN incubation in vitro, as it is summarised
in Figure 3. There are no reports, as far as we know, about
the influence of IL-2 incubation of PBMC from humans or
laboratory animals treated with retinol or retinoids. However
our findings suggesting that NK activity of PBMC from
4-HPR treated women in most cases is maximised agrees
with the observation by Fraker et al. (1986) that in BALB/c
nulnu mice NK activity is three times higher than in BALB, c
wild-type counterparts; retinol treatment p.o. of these
animals did not significantly alter cytotoxicity in niulnu, but
caused a statistically significant increase over the basal values
in wild-type mice, whose NK activity was 50% to 70%
higher than that of untreated controls. Results from
immunophenotyping indicate that functional activity, but not
the number, of the NK cells is increased in 4-HPR treated
women, as judged by the percentage of PBMC stained by
Leu 1 lb (anti CD16) MoAbs as compared to that of the two
control groups. The only similar finding reported in the
literature is that of Malter et al. (1989) who observed that in
vegetarians, whose carotene (provitamin A) concentration in
the blood is significantly augmented as compared to that of
omnivorous controls, the NK cells activity but not their
number is twice as high as that of nonvegetarians.
It is possible to hypothesise that the high basal cytotoxicity
of NK cells from 4-HPR treated women could be a function
of an increased production of endogenous IL-2. Therefore,
the amount of IL-2 produced by PBMC stimulated in vitro
was measured by means of a proliferation assay of a IL-2
dependent cell line (CTLL). We evaluated the IL-2 produc-
tion following stimulation with FLU, ALLO, PHA and
XENO, as specified in Methods. This panel of stimuli was
selected because it permits the analysis of several T helper/
Antigen Presenting Cell (Th/APC) pathways. The responses
to FLU and XENO require CD4+ Th and autologous APC.
Responses to ALLO can utilise both CD4+ and CD8+ Th
together with allogeneic or autologous APC; in contrast, the
response to PHA utilises both CD4+ and CD8+ Th, but is
less dependent on APC. The results reported in Table I show
that IL-2 production of PBMC cultures from patients treated
with 4-HPR or placebo is not significantly different prior and
after 180 days of treatment.
From the present data, it may be concluded that: (1) the
NK activity of mastectomised women treated for 180 days
with 4-HPR is significantly higher than that of those receiv-
ing a placebo, (2) the functional activity, but not the number,
of NK cells is increased in 4-HPR treated women, (3) the
basal NK activity of PBMC from 4-HPR treated women is
maximised because, being higher than the basal or rIL-2 and
alfa-rIFN stimulated thresholds in the vast majority of cases,
cannot be further augmented by incubation with either rIL-2
or alfa-rIFN in vitro, (4) IL-2 production of PBMC cultures
from patients treated with 4-HPR or placebo is not
significantly different prior to and after 180 days of treat-
ment; in other words, the increased NK activity of 4-HPR
treated women is not a function of an increased production
of endogenous IL-2, (5) incubation of PBMC of blood
donors with 4-HPR does not modify their natural cytotox-
icity, thus showing that such retinoid is active in vivo but not
in vitro, and (6) 4-HPR is not acting through its major
metabolite 4-MPR.
It is therefore of both biologic interest and of potential
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icity, since this activity may be an important component of
the antineoplastic effect of synthetic retinoid.
The present studies have been approved by the ethical committee of
the Istituto Nazionale Tumori, Milano, Italy.
The 4-HPR study is jointly supported by the Istituto Nazionale
Tumori of Milano, the Italiou C.N.R. and the NCI Grant
No. 5UOlCA38567. 4-HPR is provided at no cost by the R.W.
Johnson Pharmaceutical Research Institute of Spring House, PA,
USA.
The work was also supported by CNR-ACRO 1993 and MURST
40% 1993.
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